Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Andrew Cittadine currently holds 39,499 shares of Monopar Therapeutics (MNPR), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Andrew Cittadine has been a net buyer of MNPR stock. They have purchased $149.6K and sold $0 worth of shares.
Andrew Cittadine's most recent insider trade was on Jun 30, 2026, when they sold 5,254 shares at $0.00 per share.
Andrew Cittadine serves as Executive at Monopar Therapeutics (MNPR). They have executed 45 insider transactions totaling $149.6K over their tenure at the company.
Andrew Cittadine holds the position of Executive at Monopar Therapeutics, where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 4 years and currently hold a stake valued at $0.
Andrew Cittadine has shown a buying trading pattern, with $149.6K in total purchases and $0 in total sales across all transactions. Their most recent activity indicates a tendency to accumulate shares.
The largest transaction by Andrew Cittadine was on Jun 30, 2026, when they sold $213.8K worth of MNPR shares. This transaction involved 2,309 shares at $92.59 per share.
Andrew Cittadine currently owns 39,499 shares of Monopar Therapeutics (MNPR), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Andrew Cittadine's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Andrew Cittadine has 45 Form 4 filings on record as an insider at Monopar Therapeutics.
Set alerts for Andrew Cittadine and 40,000+ other insiders.